308 related articles for article (PubMed ID: 30914485)
1. Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists.
Mann A; Moulédous L; Froment C; O'Neill PR; Dasgupta P; Günther T; Brunori G; Kieffer BL; Toll L; Bruchas MR; Zaveri NT; Schulz S
Sci Signal; 2019 Mar; 12(574):. PubMed ID: 30914485
[TBL] [Abstract][Full Text] [Related]
2. Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.
Lu JJ; Polgar WE; Mann A; Dasgupta P; Schulz S; Zaveri NT
Mol Pharmacol; 2021 Jul; 100(1):7-18. PubMed ID: 33958480
[TBL] [Abstract][Full Text] [Related]
3. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
4. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.
Ferrari F; Cerlesi MC; Malfacini D; Asth L; Gavioli EC; Journigan BV; Kamakolanu UG; Meyer ME; Yasuda D; Polgar WE; Rizzi A; Guerrini R; Ruzza C; Zaveri NT; Calo G
Eur J Pharmacol; 2016 Dec; 793():1-13. PubMed ID: 27780725
[TBL] [Abstract][Full Text] [Related]
5. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.
Meyer ME; Doshi A; Yasuda D; Zaveri NT
AAPS J; 2021 May; 23(3):68. PubMed ID: 33974173
[TBL] [Abstract][Full Text] [Related]
7. Serine 363 is required for nociceptin/orphanin FQ opioid receptor (NOPR) desensitization, internalization, and arrestin signaling.
Zhang NR; Planer W; Siuda ER; Zhao HC; Stickler L; Chang SD; Baird MA; Cao YQ; Bruchas MR
J Biol Chem; 2012 Dec; 287(50):42019-30. PubMed ID: 23086955
[TBL] [Abstract][Full Text] [Related]
8. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
9. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
10. Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation.
Daga PR; Zaveri NT
Proteins; 2012 Aug; 80(8):1948-61. PubMed ID: 22489047
[TBL] [Abstract][Full Text] [Related]
11. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.
Thompson AA; Liu W; Chun E; Katritch V; Wu H; Vardy E; Huang XP; Trapella C; Guerrini R; Calo G; Roth BL; Cherezov V; Stevens RC
Nature; 2012 May; 485(7398):395-9. PubMed ID: 22596163
[TBL] [Abstract][Full Text] [Related]
12. Two C-terminal amino acids, Ser(334) and Ser(335), are required for homologous desensitization and agonist-induced phosphorylation of opioid receptor-like 1 receptors.
Wang HL; Kuo YL; Hsu CY; Huang PC; Li AH; Chou AH; Yeh TH; Chen YL
Cell Signal; 2006 May; 18(5):670-8. PubMed ID: 16019191
[TBL] [Abstract][Full Text] [Related]
13. Discovery and structure-activity relationships (SAR) of a novel class of 2-substituted N-piperidinyl indole-based nociceptin opioid receptor ligands.
Meyer ME; Doshi A; Polgar WE; Zaveri NT
Bioorg Med Chem; 2023 Sep; 92():117421. PubMed ID: 37573822
[TBL] [Abstract][Full Text] [Related]
14. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.
Schröder W; Lambert DG; Ko MC; Koch T
Br J Pharmacol; 2014 Aug; 171(16):3777-800. PubMed ID: 24762001
[TBL] [Abstract][Full Text] [Related]
15. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.
Toll L; Bruchas MR; Calo' G; Cox BM; Zaveri NT
Pharmacol Rev; 2016 Apr; 68(2):419-57. PubMed ID: 26956246
[TBL] [Abstract][Full Text] [Related]
16. Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
Hayashi S; Ohashi K; Mihara S; Nakata E; Emoto C; Ohta A
Eur J Med Chem; 2016 May; 114():345-64. PubMed ID: 27043173
[TBL] [Abstract][Full Text] [Related]
17. Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development.
Wtorek K; Janecka A
Chem Biodivers; 2021 Jan; 18(1):e2000871. PubMed ID: 33351271
[TBL] [Abstract][Full Text] [Related]
18. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
Zaveri NT; Jiang F; Olsen C; Polgar WE; Toll L
Bioorg Med Chem Lett; 2013 Jun; 23(11):3308-13. PubMed ID: 23623415
[TBL] [Abstract][Full Text] [Related]
19. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
Kiguchi N; Ding H; Kishioka S; Ko MC
Curr Top Med Chem; 2020; 20(31):2878-2888. PubMed ID: 32384033
[TBL] [Abstract][Full Text] [Related]
20. Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies.
Mann A; Liebetrau S; Klima M; Dasgupta P; Massotte D; Schulz S
Sci Rep; 2020 May; 10(1):8585. PubMed ID: 32444688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
